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We propose a new method to mitigate (identify and address) adverse interactions (drug–drug or drug–
disease) that occur when a patient with comorbid diseases is managed according to two concurrently
applied clinical practice guidelines (CPGs). A lack of methods to facilitate the concurrent application of
CPGs severely limits their use in clinical practice and the development of such methods is one of the
grand challenges for clinical decision support. The proposed method responds to this challenge.
We introduce and formally deﬁne logical models of CPGs and other related concepts, and develop the
mitigation algorithm that operates on these concepts. In the algorithm we combine domain knowledge
encoded as interaction and revision operators using the constraint logic programming (CLP) paradigm.
The operators characterize adverse interactions and describe revisions to logical models required to
address these interactions, while CLP allows us to efﬁciently solve the logical models – a solution repre-
sents a feasible therapy that may be safely applied to a patient.
The mitigation algorithm accepts two CPGs and available (likely incomplete) patient information. It
reports whether mitigation has been successful or not, and on success it gives a feasible therapy and
points at identiﬁed interactions (if any) together with the revisions that address them. Thus, we consider
the mitigation algorithm as an alerting tool to support a physician in the concurrent application of CPGs
that can be implemented as a component of a clinical decision support system. We illustrate our method
in the context of two clinical scenarios involving a patient with duodenal ulcer who experiences an epi-
sode of transient ischemic attack.
 2013 Elsevier Inc. All rights reserved.1. Introduction
A clinical practice guideline (CPG) [1] is a knowledge-based tool
for disease-speciﬁc patient management. It is created by a panel
of experts and is supported by medical evidence coming from spe-
cialized repositories [2] (such as The Cochrane Library [3]). A CPG
encapsulates best practices in identifying relevant patient data,
drawing conclusions from this data with regards to possible diag-
noses, and prescribing the most appropriate treatment. It is gener-
ally agreed that the use of CPGs at the point of care has a positive
impact on a patient’s outcomes and providing guidelines to physi-
cians in a computer executable format advances their adherence to
standards of practice and improves quality of care [4]. While the
ability to enact a CPG for available patient data plays an importantll rights reserved.
Wilk).role in guideline uptake by the medical profession, it does not
address the issue of using guidelines on patients with comorbid
diseases. Such a need is especially clear for elderly patients – sev-
eral studies [2,5,6] have shown that about half of people 65 years
or older have two or more comorbid conditions. The concurrent
application of disease-speciﬁc CPGs for such patients often has
undesired consequences due to the inconsistencies in the guide-
lines that lead to adverse drug–drug or drug–disease interactions
[7].
Providing methods and tools that would enable the application
of multiple CPGs to a patient with comorbid diseases has been
listed as one of the ‘‘grand challenges’’ for clinical decision support
[8]. The authors maintain that CPGs have been underutilized in
practice because they have not accounted for co-morbidity issues.
At the same time the authors call for new ‘‘combinatorial, logical,
or semantic approaches’’ that would allow for merging several
CPGs and cross-checking their recommendations. The call for
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checking for inconsistencies and adverse interactions) has been re-
peated in [9].
The method proposed in this paper responds to these calls. It
builds on our earlier research [10,11] that applied constraint logic
programming (CLP) [12] to identify adverse interactions resulting
from using multiple guidelines on the same patient. However, cur-
rent research signiﬁcantly expands our past work by:
 Introducing logical models of analyzed CPGs that act as an inter-
mediate layer between common CPG representations and CLP
models.
 Introducing interaction and revision operators that codify
domain knowledge indicating possible adverse interactions
between logical models and describing necessary revisions of
the models.
 Proposing a new algorithm (further referred to as the mitigation
algorithm) that operates on the logical models and uses opera-
tors in order to identify and address adverse interactions that
are demonstrated by the concept of a potential source of
infeasibility.
From a clinician’s perspective we see our method (the mitiga-
tion algorithm in particular) as an ‘‘alerting tool’’ to support the
physician in the concurrent application of multiple CPGs by warn-
ing about possible adverse interactions that may occur and by sug-
gesting a clinically appropriate resolution of these interactions.
In order to ground our approach, we make the following simpli-
fying assumptions:
 The number of mitigated CPGs is limited to two due to compu-
tational and logical complexities associated with the identiﬁca-
tion and resolution of adverse interactions.
 A CPG does not include parallel actions that can be followed
concurrently (however, they can be replaced by a single
sequence of actions).
 Temporal aspects of CPG modeling and execution are not taken
into account (we only consider situations where guidelines are
applied during a single patient-physician encounter).
 There is full semantic interoperability between the CPGs.
 A CPG is revised so it does not contain sub-guidelines (if sub-
guidelines are present, they are expanded and included in the
main guideline).
In Section 5 we describe how some of the above assumptions
might be relaxed. Additionally, we assume individual CPGs are log-
ically coherent, thus it is always possible to derive a feasible ther-
apy if a single guideline is applied to a patient. This assumption is
consistent with the intended purpose of a CPG in practice (i.e., it is
designed to always propose a therapy for a given patient).
The paper is organized as follows. We start with related work.
This is followed by a description of methodologies, including a
brief presentation of the CLP paradigm, and a detailed description
of our method. Then we illustrate our proposal using a simpliﬁed
clinical case study. We conclude with a discussion and present
areas for future research.2. Related work
Related research on advanced analysis and processing CPGs falls
under the following categories: (1) verifying a CPG [13–15], (2)
using a CPG to critique actual actions [16,17], and (3) combing
multiple CPGs for a patient with comorbid diseases [18–22]. The
common theme shared by all categories is expressing processed
CPGs using one of the computer-interpretable representations(e.g., GLIF3, SAGE, Asbru or PROforma, see [23–25] for a review)
or ontological modeling.
The goal of CPG veriﬁcation is early identiﬁcation (before a
guideline is applied to a patient) of issues such as semantic errors
and inconsistencies in the deﬁnition of a guideline. Three types of
methods are employed for this purpose: theorem proving [14],
model checking [13] and knowledge-based checking [15]. Theo-
rem proving implies representing a CPG as a theory that can be
processed by an automatic theorem prover, and a failed proof indi-
cates problems with the CPG. The use of theorem proving is de-
scribed for example in [14], where the authors proposed a
translation of Asbru constructs into a format acceptable by the
KIV prover and applied it in order to verify two CPGs. Model check-
ing methods assume checking a formal model of the CPG (usually
obtained from its computer-interpretable representation) against a
set of speciﬁcations describing expected properties of the guideline
model. Speciﬁcations that cannot be veriﬁed indicate problems in
the CPG. For example, in [13] the authors proposed a framework
where a CPG represented as an UML state chart is being checked
against a set of common types of the requirements in the form of
temporal logical statements. Finally, knowledge-based checking
methods employ methodologies developed for rule-based systems,
where a CPG is represented as a set of rules that are being veriﬁed
for possible anomalies (e.g., semantic errors). Deﬁnitions of anom-
alies can be either generic or domain-speciﬁc and are derived using
expert knowledge. Such a knowledge-based checking method is
described in [15], where the authors identify anomalies as unsatis-
ﬁable conditions, unreachable sequence of states or ambiguous
state transitions.
Research on critiquing looks at comparing actual actions per-
formed by a clinician to ‘‘ideal’’ actions suggested by a CPG in order
to identify various types of non-compliance (e.g., conﬂicting ac-
tions). While conceptually different from CPG veriﬁcation (critiqu-
ing is used when a CPG is being applied to a patient), it often uses
similar methods, mostly model checking. In [16] the authors pro-
posed an approach where a CPG represented as a state transition
model is being checked against a set of temporal logic formulas
describing actual actions. The proposed approach is able to identify
two classes of non-compliance – related to actions (e.g., conﬂicting
or missing mandatory actions) and related to clinical ﬁndings or
patient data (e.g., missing relevant ﬁndings or wrong ﬁnding for
a given action). A different approach to critiquing is presented in
[17], where a CPG is translated into a set of ‘‘if conditions, then crit-
icize’’ rules that are further used to verify treatments prescribed by
physicians, and to provide additional explanation why a particular
treatment should not be recommended.
It is worth mentioning that there are approaches combining
CPG veriﬁcation with compliance assessment for more compre-
hensive decision support. For example, the approach described in
[26] uses an ontological model of domain knowledge together with
abductive reasoning to evaluate whether a CPG is complete and
appropriate (in terms of suggested actions and their justiﬁcation),
and to assess the compliance of a physician’s actions with a CPG.
Moreover, it provides support when executing a CPG by summariz-
ing and explaining observed patient’s clinical states and by warn-
ing about the violation of so-called safety rules. These rules are
part of the ontological model and characterize adverse drug–drug
or disease–drug interactions; they may also explain how speciﬁc
interactions can be prevented.
Despite its clinical importance, research on combining multiple
CPGs is in its early stages – as stated in [18], combining multiple
CPGs ‘‘is not a trivial task’’. Proposed solutions vary from manual
interventions, where human experts combine CPGs using a special-
ized editing tool [19], through semi-automatic approaches, where
experts resolve automatically discovered conﬂicts [18], to fully
automatic approaches that employ codiﬁed expert knowledge
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being executed [20–22]. In [22] the authors described an approach
for combining multiple CPGs using the SDA representation [27].
Their method translates each of the combined CPGs into a set of
state-action pairs, expands them into state-action-prognosis tri-
ples using prognosis rules, and ﬁnally merges these triples into a
single CPG. Merging is driven by restriction and substitution rules.
The former indicate states that cannot be combined together, while
the latter indicate drug interactions that may arise in combined ac-
tions and prescribe how to address them. Prognosis, restriction and
substation rules need to be deﬁned by experts or they can be dis-
covered from data using data mining techniques [21]. Another ap-
proach to combining multiple CPGs that is based on ontological
models is described in [20]. The models represent individual CPGs
and they are merged along common actions, decisions, concepts
and locations using mapping and alignment constructs associated
with ontology.
The rationale behind the research described in this paper is to
respond to the postulates presented in [8,9] by proposing a method
that veriﬁes if multiple CPGs can be applied concurrently to a pa-
tient with comorbid diseases, and introduces necessary modiﬁca-
tions when such application is not feasible. The proposed method
differs in several aspects from what has been presented so far. It
allows for rich deﬁnitions of interactions that involve states and
actions thus they go beyond drug–drug interactions. It requires
no additional expert knowledge beyond the deﬁnition of interac-
tion and revision operators (in other words there is no need for
prognosis rules that may be difﬁcult to deﬁne). Finally, the analysis
and processing is driven by available patient data, thus it allows for
personalization and customization of the resulting CPGs. Our
method also shares some similarities with the approaches re-
viewed above. Similarly to CPG veriﬁcation, it employs models of
the CPGs (logical models in particular) for analysis and processing.
Similarly to critiquing techniques, it uses available patient data as
input information. In terms of checking for adverse interactions be-
tween the CPGs, it uses interaction operators that are conceptually
similar to the safety rules proposed in [26] and restriction rules
proposed in [22]. Moreover, to address adverse interactions our
method uses revision operators that play similar role to substitu-
tion rules proposed in [22].
From a general perspective, our method can be placed in the
broad category of meta-level control and reasoning methods in
medicine [28,29], and our approach to dealing with the adverse
interactions in multiple CPGs shares similarities with conﬂict res-
olution methods in automated reasoning [30].3. Methodology
We consider a situation when two CPGs are applied to a patient
with comorbid diseases in order to obtain a combined therapy. A
typical situation would involve a chronic disease and an acute dis-
ease, although other cases (e.g., two acute conditions) are also
admissible. A combined therapy consists of two individual thera-
pies derived from disease-speciﬁc CPGs. Given a patient’s state
(characterized by available patient information) a feasible com-
bined therapy does not exist, if there are direct adverse interac-
tions between individual actions that manifest as contradictory
recommendations (e.g., ‘‘take aspirin’’ in one CPG and ‘‘don’t take
aspirin’’ in the other). Even, if there are no direct interactions, indi-
vidual therapies need to be further checked for indirect adverse
interactions that are caused by drug–drug or drug–disease interac-
tions and in most cases are not explicitly represented in the
guidelines.
If none of the adverse interaction (direct or indirect) has been
encountered, then a feasible combined therapy can be formulated.On the other hand, if the combined therapy cannot be formulated,
disease-speciﬁc CPGs and associated therapies need to be revised
using clinical knowledge that goes beyond what is encoded in
the guidelines and comes from domain experts, textbooks, or
repositories of clinical evidence.
We call the process of checking for and addressing adverse
interactions (direct or indirect) mitigation. In practice, when man-
aging a comorbid patient a physician mitigates interactions be-
tween guidelines manually and during this process she relies on
clinical acumen (and evidence). Our intention is to automate this
mitigation process by:
1. Representing CPGs as ‘‘computable’’ logical models (discussed
in Section 3.2.2).
2. Representing clinical acumen using two types of operators –
interaction operators (discussed in Section 3.3.1) that character-
ize indirect adverse interactions, and revision operators
(discussed in Section 3.3.2) that describe possible revisions to
the logical models of CPGs.
3. Introducing a dedicated mitigation algorithm (discussed in Sec-
tion 3.4) that processes logical models of considered CPGs,
checks for possible adverse interactions and addresses them
using the operators.
The mitigation algorithm forms the core of our method as it
brings together logical models and operators and applies the CLP
paradigm (outlined in Section 3.1) to solve the models given avail-
able patient data. The existence of a solution implies the ability to
formulate a feasible combined therapy, while the lack of a solution
indicates the presence of adverse interactions. The source of these
interactions, further called potential source of infeasibility (see Sec-
tion 3.2.5), is identiﬁed with the help of interaction operators and
addressed with the help of revision operators. The high level over-
view of the mitigation algorithm is given in Fig. 1. The algorithm is
composed of three phases: (1) creating logical models of CPGs, (2)
mitigating direct adverse interactions and (3) mitigating indirect
adverse interactions. The algorithm may terminate after the sec-
ond phase if it has failed to mitigate direct interactions.
3.1. Constraint logic programming
CLP uniﬁes logic programming (LP) and a constraint satisfaction
problem (CSP) by using LP as a constraint programming language
to solve a CSP [12]. A logic program is seen as logical theory com-
posed of a set of rules called clauses. CLP extends it by including
constraints in the body of clauses, and querying the program about
the provability of a goal produces a solution to the CLP. The proof
for the goal is composed of clauses whose bodies are satisﬁable
constraints.
A CLP model follows the CSP nomenclature. As such it is made
up of a set of variables, a set of clauses with constraints and a goal
to be satisﬁed, that deﬁne the logic program. The clauses in the
model capture the relationships between variables and they re-
strict the possible combinations of values assigned to variables.
Solving a CLP model entails satisfying the goal given the set of con-
straints, where a value is assigned to each variable such that no
constraints are violated (bodies of all clauses are satisﬁed). Vari-
ables related to available information are instantiated prior to solv-
ing the model and cannot be revised by the solving procedure.
3.2. Basic concepts
In order to illustrate selected formal concepts introduced in this
section we use a clinical case involving the concurrent application
of CPGs for deep vein thrombosis (DVT) and uncontrolled hyper-
tension (UHTN). While this example has been simpliﬁed to better
Phase 3Phase 2Phase 1
Direct 
interactions exist ?
Check for direct 
adverse interactions
Direct interactions 
addressed?
Address all direct 
adverse interactions 
Indirect 
interactions exist?
Check for indirect 
adverse interactions
Indirect interactions 
addressed?
Address all indirect 
adverse interactions 
Yes
No
Yes
Failure
Success
Yes
No
Yes
NoNo
Create logical models of 
CPG1 and CPG2
CPG1 CPG2
Available 
patient 
information
Interaction and 
revision operators
Fig. 1. Overview of the mitigation algorithm.
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ically valid and it was prepared with help of a clinical expert.Fig. 2. Sample actionable graphs.3.2.1. Actionable graph
Our method focuses on efﬁcient processing of CPGs and to make
it independent of any speciﬁc CPG representation, we have intro-
duced the concept of an actionable graph as the way to express
the guidelines. This concept has been inspired by the SDA formal-
ism [27] – one of the most recent CPG representations that builds
on the well-established foundations (e.g., Asbru and PROforma)
and addresses many of their shortcomings (e.g., complexity that
makes them difﬁcult to understand and use by healthcare profes-
sionals). An actionable graph is a simpliﬁed version of the SDA
representation and it can be easily obtained from any CPG repre-
sentation that distinguishes between context, decision and action
steps (according to [25] these steps are common for most CPG rep-
resentations, including Asbru, PROforma or GLIF3).
An actionable graph (AGi) for a speciﬁc CPG (denoted as CPGi) is
deﬁned as a directed graph:
AGi ¼ hNi;Aii;
where Ni is a set of context, action and decision nodes, and Ai is a set
of arcs representing transitions between nodes. A context node pro-
vides a clinical context at a speciﬁc point in CPGi. AGi has a context
node as its root (starting node) that deﬁnes an entry point and la-
bels the disease managed by CPGi. An action node corresponds to
an action step from CPGi and indicates a task that needs to be con-
ducted. A decision node corresponds to a decision step and indi-
cates selection of one from several alternative choices that are
associated with the arcs emanating from this decision node.
Examples of actionable graphs representing simpliﬁed CPGs for
DVT and UHTN are given in Fig. 2. In this ﬁgure the context node is
indicated with an oval, decision nodes are indicated withdiamonds, and action nodes with rectangles. Moreover, the ﬁgure
labels variables associated with speciﬁc nodes and values corre-
sponding to alternative choices – they are given in square brackets
after node and choice descriptions. For example, the SBT variable is
associated with the ‘‘history of severe bleeding tendency’’ decision
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present and absent. They are represented as p and a values respec-
tively (these values deﬁne the domain of the SBT variable).3.2.2. Logical model
A logical model (LMi) provides a logical representation of an AGi
and is deﬁned as:
LMi ¼ hdi; Vi; PLEii;
where di is the label of a disease retrieved from the context node of
AGi, Vi is a set of action and decision variables associated with ac-
tions and decision nodes in AGi respectively, and PLEi is a set of log-
ical expressions representing paths in AGi, each being a conjunction
of variable-value pairs. Action variables are Boolean – true value as-
signed to an action variable means that an action should be carried
out, while false indicates it should not. Decision variables have do-
mains deﬁned by possible alternative choices and assigning a spe-
ciﬁc value to a decision variable indicates making a speciﬁc choice.
Sample logical models created from actionable graphs in Fig. 2
are given in Fig. 3 (their creation is described in detail in Sec-
tion 3.4). In all logical expressions in Fig. 3 and in the following text
we use a simpliﬁed notation for Boolean variables – i.e., V = true is
denoted simply as V, while V = false as :V .
A combined logical model (CLMi,j) brings together the pair of log-
ical models deﬁned above and information about possible adverse
interactions between the underlying CPGs. It is deﬁned as:
CLMi;j ¼ hLMi; LMj; ILEi;ji;
where ILEi,j is a set of logical expressions that represent adverse
interactions between CPGi and CPGj.
A combined logical model for DVT and UHTN (CLMDVT,UHTN) in-
cludes both logical models from Fig. 3 and for the sake of brevity
we do not repeat them here.3.2.3. CLP-CPG model
A CLP-CPG model (CCMi,j) constitutes a solvable representation
of CLMi,j. It is deﬁned as:
CCMi;j ¼ hVi;j; CLi;ji;
where Vi,j is a set of variables such that Vi,j = Vi [ Vj and CLi,j is a set of
constraints established from PLEi, PLEj and ILEi,j.
A CLP-CPG model for a single CPGi is a speciﬁc instance of the
CCMi,j where Vi,j = Vi and CLi,j is created from PLEi only.Fig. 3. Sample logical models.3.2.4. Solution
A solution to CCMi,j (labeled as SOLi,j) is deﬁned as an assign-
ment of values to all variables from Vi,j such that all constraints
from CLi,j are satisﬁed.
Note that SOLi,j provides truth evaluations of the logical expres-
sions from PLEi and PLEj. Considering that actionable graphs do not
allow for parallel paths to be traversed simultaneously, there is
only one expression from PLEi and one from PLEj that is evaluated
as true (each of these two expressions corresponds to a disease-
speciﬁc therapy). Therefore, a solution of CCMi,j that is presented
to a physician includes variable-value pairs that appear in these
two expressions (as opposed to value assignments to all variables)
– more speciﬁcally it includes variable-value pairs for all decision
variables in these expressions and action variables assigned true.
Thus, the ﬁltered solution represents a combined therapy and it
points out actions that have been done or should be done for a pa-
tient and indicates decisions (actual or inferred) under which these
actions are valid.
3.2.5. Potential source of infeasibility
The lack of a solution to CCMi,j indicates the inability to ﬁnd a
set of variable-value pairs satisfying all constraints. Violated con-
straints provide valuable information about the source of infeasi-
bility in the model and we use this information in deﬁning a
potential source of infeasibility (PSIi,j). Speciﬁcally, PSIi,j is deﬁned
as a set of variables from Vi,j that appear in violated constraints
from the CLi,j.
We assert our assumption that an individual CPG is logically
consistent (there is always a sequence of action and decision steps
that corresponds to a path in a related actionable graph), and thus
the associated CLP-CPG model must always have a solution. Conse-
quently, the lack of a solution can only occur when a CLP-CPGmod-
el is derived from two CPGs.
3.3. Operators
Operators are applied to CLMi,j and each is composed of activa-
tion and knowledge components. The activation component de-
ﬁnes when an operator is applicable (i.e., when it can be
activated), and the knowledge component establishes revisions
to be introduced to CLMi,j.
In order to illustrate both types of operators we use the same
clinical case as in Section 3.2.
3.3.1. Interaction operator
An interaction operator (IOk) is deﬁned as a 3-tuple:
IOk ¼ hDk; Vk; leki;
where Dk is a set of disease labels (it can include a wildcard value ‘’
that indicates any disease label), Vk is as set of variables and lek is a
logical expression. Dk and Vk form the activation component, and lek
forms the knowledge component codifying a single adverse interac-
tion that is added to ILEi,j.
Considering the illustrative clinical case, adverse interactions
may occur when a patient with hypertensive urgency (deﬁned as
elevated blood pressure above 180/110) is treated with warfarin
because of the danger of hypertensive crisis. Such indirect adverse
interaction is codiﬁed by the interaction operator given in Fig. 4.
This operator contains the wildcard in its ﬁrst component, thus it
is activated for any combined logical model that includes variablesFig. 4. A sample interaction operator.
Fig. 5. A sample revision operator.
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Then, the expression given as the third component and describing
the adverse interaction between hypertensive urgency (TUHT-
N = ur) and provision of warfarin (WA = true) is added to the ILEi,j
component of the combined logical model.
3.3.2. Revision operator
A revision operator (ROk) is deﬁned as 4-tuple:
ROk ¼ hDk; Vk; slek; tleki
where Dk is a set of disease labels (as previously, it can also include
the ‘’ wildcard), Vk is a set of variables and slek and tlek are logical
expressions. Similarly to IOk, Dk and Vk form the activation compo-
nent, and slek and tlek form the knowledge component. The knowl-
edge component of ROk states that whenever slek appears in logical
expressions from ILEi or ILEj, it is replaced by tlek.
A sample revision operator that addresses the interaction de-
scribed by the interaction operator from Fig. 4 is given in Fig. 5.
This operator is activated whenever the identiﬁed possible source
of infeasibility contains variables TUHTN and WA (i.e., has been
caused by the interaction presented in Section 3.3.1). It revises
the combined logical model by identifying all the logical expres-
sions describing paths in actionable graphs that imply treating a
patient with warfarin (WA = true) and discouraging the use of IVC
(inferior vena cava) ﬁlter (IVCF), and replacing them with an
expression that discards warfarin and replaces it with the IVC ﬁlter.
3.4. Mitigation algorithm
The mitigation algorithm is composed of a number of proce-
dures that are described in details below. The main procedure,
called mitigate, implements the ﬂow of the algorithm (see Fig. 1)Fig. 6. Pseudo-code for thand invokes the auxiliary procedures. The algorithm assumes that
all interaction and revision operators have been deﬁned and stored
in an accessible and easy to search repository. The creation of oper-
ators is a research topic in itself and for the sake of simplicity we
assume the repository with operators is prepared manually with
the help of medical experts. This assumption is in line with recent
attempts to create a centralized and shared repository with stan-
dardized drug–drug interactions [31].
The pseudo-code for the mitigate procedure is given in Fig. 6.
The procedure accepts as input actionable graphs (AGi and AGj)
and available patient information (PI) given as a set of variable-
value pairs. It reports success if both CPGs can be concurrently ap-
plied to the patient and failure otherwise. It also provides additional
and more detailed results as output parameters. They include a
possible solution of the CLP-CPG model (SOLi,j), potential source of
infeasibility (PSIi,j) and the revision operator that addresses it
(ROk). Possible combinations of the returned values and output
parameters together with their interpretations are given in Table 1.
The mitigate procedure starts by constructing logical models
(lines 1–3).Models that represent actionable graphs are constructed
by the create_LM procedure (see Fig. 7) that takes an actionable
graph (AGi) as an input and reports a logical model (LMi) on output.
The create_LM procedure is relatively simple, only the conversion of
a path from AGi to a logical expression (line 4) requires some expla-
nation. A path including nodes n1p;n
2
p; . . . ; n
k
p is converted into a con-
junction of terms according to the following rules:
 If nmp is a context node, then it is discarded,
 If nmp is an action node, then (Vmp ¼ true) is added to the conjunc-
tion, where Vmp is the action variable associated with the node
nmp ,
 If nmp is a decision node, then (Vmp ¼ amp ) is added to the conjunc-
tion, where Vmp is the decision variable associated with the node
nmp and V
m
p is an alternative choice linked to the arc emanating
from nmp and traversed in the considered path.
 Finally, for each action node nm which is not included in the
path, (Vm ¼ false) is added to the conjunction, where Vm is thee mitigate procedure.
Table 1
Returned values and output parameters of the mitigate procedure.
Returned
value
SOLi,j PSIi,j RO
k Interpretation
Success Not
null
Null Null Both CPGs (represented as AGi and AGj) can be applied concurrently; there is no infeasibility given the available patient
information (PI) that needs to be addressed. A solution (SOLi,j) is returned
Success Not
null
Not
null
Not
null
Both CPGs (represented as AGi and AGj) can be applied concurrently; a potential source of infeasibility (PSIi,j) has been
encountered, but it was successfully mitigated with the revision operator (ROk). A solution (SOLi,j) together with mitigation
information are returned
Failure Null Not
null
Null Both CPGs (represented as AGi and AGj) cannot be applied concurrently. The encountered source of infeasibility (PSIi,j) cannot be
addressed by the available revision operators and no solution exists
Fig. 7. Pseudo-code for the create_LM procedure.
Fig. 8. Pseudo-code for the solve_CCM procedure.
Fig. 9. Pseudo-code for the address_PSI procedure.
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path are not realized.
The logical models created by create_LM are put together into
the combined logical model (CLMi,j). The ILEi,j component of the
CLMi,j model is initially empty – indirect adverse interactions are
considered only in the third phase of the algorithm.
After creating the logical models, the mitigate procedure pro-
ceeds to the second phase of the algorithm (lines 4–12) where it
identiﬁes and addresses direct adverse interactions. First, the sol-
ve_CCM procedure (see Fig. 8) is invoked to create a CLP-CPGmodel
(CCMi,j) from the CLMi,j model and to solve CCMi,j given available
patient information (PI). On success it reports a solution (SOLi,j),
and on failure (no solution) it reports the potential source ofinfeasibility (PSIi,j). Creation of constraints in the CCMi,j model (line
2) requires additional explanation. The ﬁrst two constraints in the
CLi,j component of CCMi,j are disjunctions of all logical expressions
in PLEi and PLEj – they ensure one path in each underlying action-
able graph will be traversed. Next, each expression from ILEi,j is
negated and becomes a separate constraint to ensure that indirect
interactions are avoided. In fact, these constraints are created only
in the last phase of the algorithm (when indirect adverse interac-
tions are being mitigated), as in earlier phases ILEi,j is empty. Then,
the CCMi,j model is solved using a CLP solver.
If no solution has been found by the solve_CCM procedure,
indicating the presence of direct adverse interactions, the mitigate
procedure invokes address_PSI (see Fig. 9) in order to address the
reported potential source of infeasibility (PSIi,j). The address_PSI
Fig. 10. Pseuo-code for the activate_ROs procedure.
Fig. 11. Pseudo-code for the revise_CLM nad revise_LM procedures.
Fig. 12. Pseudo-code for the apply_IOs procedure.
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solvability of the derived CLP-CPG model given available patient
information (PI). It ﬁrst invokes activate_ROs (see Fig. 10) to acti-
vate applicable restriction operators and to obtain their ordered
list (ARO). The operators are ordered according to the scope of
changes (operators that introduce smaller number of revisions
are preferred), and in the case of a tie, they are ordered according
to the number of variables from PSIi,j covered by the operator
(operators that cover more variables are preferred). Then, ad-
dress_PSI iterates over ARO and in each iteration it attempts to re-
vise the CLMi,j model using the current operator (ROk) and to solve
the derived CLP-CPG model (line 4).
Revision are introduced by the revise_CLM and revise_LM proce-
dures (see Fig. 11) that apply ROk to logical models and report suc-
cess or failure depending whether any revisions have been made or
not. A revised CLMi,j may include new variables and if revise_CLM is
called during the last phase of the algorithm, it invokes the ap-
ply_IOs procedure (see Fig. 12) to update the ILEi,j component of
the revised CLMi,j model with logical expressions describing all
possible indirect interactions.
The address_PSI procedure solves the model revised by revi-
se_CLM (CLM0i;j). If the revised model still does not have a solution,
the procedure applies the next revision operator from the ARO listuntil a solution is found or until all activated revision operators
have been considered. In the latter case the mitigate procedure ter-
minates with failure (lines 9–10) to signal that direct interactions
could not be addressed.
We would like to point at two elements that improve the oper-
ation of the part of the mitigate procedure that corresponds to the
second phase of the algorithm (i.e., mitigating direct adverse inter-
actions). First, the procedure checks for direct interactions only if
there are variables shared between logical models (line 4). Second,
the potential source of infeasibility is narrowed down to the shared
variables (line 7), thus subsequent operations require a smaller
number of attempts. It is possible to focus only on shared variables
because of our assumption that individual guidelines (and their
corresponding logical models) are consistent and always have a
solution.
The last part of the mitigate procedure (lines 13–25) corre-
sponds to the third phase of the algorithm – identifying and
addressing indirect adverse interactions. First, apply_IOs is invoked
(line 13) to expand the the ILEi,j component of the CLMi,j model
with logical expressions characterizing possible indirect interac-
tions. The remaining steps are similar to what takes place in the
second phase of the algorithm. The expanded CLMi,j model is solved
using solve_CCM (line 14). In this phase of the algorithm the ILEi,j
S. Wilk et al. / Journal of Biomedical Informatics 46 (2013) 341–353 349component is not empty, thus the CCMi,j model now includes addi-
tional constraints. The existence of a solution indicates the lack of
indirect interactions, thus the mitigate procedure ﬁlters the solu-
tion (see Section 3.2.4) and terminates with success (lines 15–
17). Otherwise the procedure again invokes address_PSI to address
the potential source of infeasibility (line 19). Depending on the re-
sult (solvability of the revised combined logical model) themitigate
procedure reports either failure (line 21) or success (line 24).
4. Case study: concurrent management of duodenal ulcer and
transient ischemic attack
In this section we illustrate the use of our method in two clinical
scenarios that involve a chronic disease and an acute condition. InFig. 13. Actionable graphs represboth scenarios a patient that is treated for a duodenal ulcer (DU)
experiences an episode of transient ischemic attack (TIA). CPGs
used in this example are based on the guidelines published by
the National Institute for Health and Clinical Excellence, UK (NICE)
[32] and they have been simpliﬁed to include only the crucial ac-
tion and decision nodes.
4.1. Actionable graphs
Transforming a CPG from a formal representation into an
actionable graph is relatively straightforward – we proposed an
algorithm in [33]. Fig. 13 presents actionable graphs constructed
from CPGs for DU and TIA guidelines respectively. It employs the
same notation as used in Fig. 2, i.e., ovals for context nodes,enting the case study CPGs.
Fig. 14. Interaction and revision operators for DU and TIA.
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previously, the ﬁgure labels variables associated with speciﬁc
nodes and values corresponding to alternative choices.Fig. 15. Logica
Fig. 16. Combined logical model
Fig. 17. CLP-CPG model for4.2. Operators
Operators developed for this case study are given in Fig. 14. As
indicated earlier the operators have been created with help from
the medical expert on our team. The interaction operator (IO1) rep-
resents a drug–disease interaction (increased risk of bleeding) that
occurs when a DU patient is prescribed aspirin (A) without a pro-
ton-pump inhibitor (PPI). The revision operator RO1modiﬁes the
therapy for a DU patient by replacing aspirin with clopidogrel
(CL), if aspirin is prescribed without dipyridamole (D). Revision
operator RO2 modiﬁes the therapy for a DU patient by adding al models.
for DU and TIA (CLMDU,TIA).
DU and TIA (CCMDU,TIA).
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dipyridamole.
4.3. Clinical scenario 1: no adverse interactions
In this scenario we assume a patient who has tested positive for
Helicobacter pylori (H. pylori) (HP := p), is undergoing eradication
therapy (ET := true), on presentation to the emergency department
with TIA symptoms has tested negative for hypoglycemia (HG := n)
and has failed the FAST test (FAST := n).
The mitigation algorithm invokes the mitigate procedure with
the following input parameters: AGDU, AGTIA and available patient
information PI := {HP := p, ET := true, HG := n, FAST := n}. It starts
by calling the create_LM procedure to create logical models LMDU
and LMTIA (see Fig. 15). This is followed by the construction of
the combined logical model CLMDU,TIA with ILEDU,TIA being empty.
Logical models LMDU and LMTIA do not share variables, thus di-
rect adverse interactions are absent. Themitigate procedure checks
for indirect adverse interactions. It ﬁrst invokes the apply_IOs pro-
cedure to modify the CLMDU,TIA model by applying IO1. The result-
ing model is shown in Fig. 16 (logical models LMDU and LMTIA are
given in full in Fig. 15 and for the sake of brevity are not repeated).
Next, the solve_CLM procedure constructs the CCMDU,TIA model
(given in Fig. 17) from CLMDU,TIA and successfully solves it given
patient information PI. A solution, ﬁltered to return only relevant
actions and decisions, is as follows: SOLDU,TIA := {HP := p, ET := true,
PPI := true, UE := h, SC := true, HG := n, FAST := n, PCS := true}. It indi-
cates that the patient in question should be given PPI (PPI := true).
Also, since the result of the endoscopy (UE) is not given (not intro-
duced to the model as part of PI), the CLP solver has selected a ther-
apy corresponding to a healed ulcer (UE := h) and involving referral
to self-care (SC := true).
4.4. Clinical scenario 2: adverse interactions present
In this scenario we consider a patient who has tested negative
for H. pylori (HP := n), positive for Zollinger–Ellison syndrome
(ZES := p), and who on presentation to the emergency department
with TIA symptoms has tested negative for hypoglycemia (HG := n),
passed the FAST test (FAST := p) and has had neurological symp-
toms resolved (NS := r).
Initial operations of the mitigate procedure are the same as in
Scenario 1 (the same logical models as given in Figs. 15 and 16
are constructed). Considering the available patient information
the CCMDU,TIA model does not have a solution, because of the vio-
lated constraint (:(A ^ PPI)) that indicates the presence of indirect
adverse interactions. The potential source of infeasibility is identi-
ﬁed by the CLP solver as PSIDU,TIA := {A, PPI} and the algorithm in-
vokes the address_PSI procedure.
The activate_ROs procedure is called to activate and order
applicable revision operators. Activated revision operators are
iteratively applied to CLMDU,TIA. RO2 is tried ﬁrst (it introduces less
changes than RO1) – the revise_CLM and revise_LM procedures are
called to create CLM’DU,TIA – a revised version of CLMDU,TIA, where
PLETIA has been modiﬁed by replacing A ^ D with A ^ D ^ PPI where
applicable. The solve_CCM procedure is invoked to solve a CLP-CPG
model constructed from CLM0DU;TIA. A solution still does not exist
due to direct adverse interaction related to PPI (it should be pre-
scribed according to the revised TIA guideline, while it shouldn’t
according to the DU guideline).
Since RO2 has failed to address PSIDU,TIA, RO1 is now applied.
Again, revise_LM and revise_CLM are called to make the revisions
– PLETIA is modiﬁed by replacing A ^ :D with :A ^ :D ^ CL when
necessary, and another CLM0DU;TIA is constructed. Invocation of the
solve_CCM procedure is successful and a solution ﬁltered to rele-
vant actions and decisions is SOLDU,TIA := {HP := n, ZES := p,RS := true, HG := n, FAST := p, NS := r, RST := ng, CL := true,
PCS := true}. The mitigation algorithm returns success and reports
the solution SOLDU,TIA, the potential source of infeasibility PSIDU,TIA
and the successfully applied revision operator RO1.
The solution SOLDU,TIA indicates a therapy where clopidogrel
should be prescribed (CL := true) and the patient should be referred
to primary care specialist (PCS := true). Considering that the risk of
stroke (RST) is not given (and therefore value of corresponding var-
iable has not been introduced to the algorithm as part of the pa-
tient information PI), the CLP solver has selected a therapy
corresponding to negligible risk (RST := ng) because it is the only
one that is feasible.5. Discussion and conclusions
In this paper we presented a method for processing pairs of con-
currently applied CPGs that at its core has an algorithm for mitigat-
ing adverse interactions. The algorithm takes CPGs represented as
actionable graphs and accepts incomplete patient data. Consider-
ing the logical complexity of mitigating adverse interactions, the
algorithm does not support parallel paths in the guidelines (such
paths need to be pre-processed and expanded). Its operation starts
by creating logical models from actionable graphs. Logical models
are further transformed into a CLP-CPG model that is solved given
patient data – if a solution exists, it represents a feasible combined
therapy. A lack of a solution (related to a potential source of infea-
sibility) indicates adverse interactions between the guidelines and
an attempt to address them is automatically initiated. Mitigating
adverse interactions requires clinical knowledge that goes beyond
what is presented in the guidelines. This knowledge can come from
medical experts (as in our example), textbooks, repositories of clin-
ical evidence or centralized repositories of interactions [31]. We
encode this knowledge as two types of operators – interaction
operators that characterize indirect adverse interactions, and revi-
sion operators that describe possible revisions to logical models.
We note that logical models form the cornerstone of the mitiga-
tion algorithm. They can be easily obtained from actionable graphs,
processed using interaction and revision operators and trans-
formed into CLP-CPG models handled by efﬁcient CLP solvers.
While it would be possible to modify the mitigation algorithm so
it accepts CPGs in one of the well-known representations (e.g., As-
bru) instead of actionable graphs and translates them directly into
logical models, replacing the logical formalism entirely with an-
other representation would require major changes to the algorithm
and could affect its efﬁciency, especially if this new representation
requires a more complex translation into CLP-CPG models.
Using illustrative clinical scenarios we have shown how our
method can automatically process two CPGs, develop a comput-
able model that can be checked for adverse interactions, and ad-
dress these interactions if possible. Providing such, even limited,
support for the concurrent application of the guidelines is an
important step in the process of creating a point of care decision
support system for the management of comorbid patients.
Building further on the research described in this paper, there
are ﬁve key issues we are working on:
1. Expanding the methodology to accept more than two CPGs at a
time. While the proposed concepts are general enough, the
increased complexity associated with operating on multiple
guidelines requires substantial changes to the mitigation
algorithm.
2. Providing direct support for evaluating parallel paths in the
guidelines. This requires revisiting the deﬁnitions of logical
models and a new process of translating them into CLP-CPG
models.
Fig. 18. Envisioned implementation of the mitigation algorithm.
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guidelines. This asks for hierarchical logical models and appro-
priate changes in the mitigation algorithm.
4. Allowing for dosages of medications for a richer description of
actions and adverse interactions. This requires revisiting deﬁni-
tions of logical models and operators.
5. Allowing for the automatic extraction of clinical knowledge
from diversiﬁed sources for encoding as interaction and revi-
sion operators.
The ultimate goal of our research is to implement the mitigation
algorithm as part of MET3 – our multi-agent clinical decision sup-
port system (CDSS) [34,35]. To this end we have already developed
a pilot version of the algorithm. The pilot is implemented as a Java
application that invokes an external CLP solver to solve CLP-CPG
models. Speciﬁcally, we have employed the ECLiPSe solver [36] be-
cause it provides a specialized library (called repair) to monitor
constraints and to retrieve violated ones – this signiﬁcantly facili-
tates the identiﬁcation of a possible source of infeasibility in the
solve_CCM procedure (see Fig. 8). Moreover, the use of a specialized
CLP solver ensures appropriate computational performance of the
implemented algorithm. Currently available CLP solvers can efﬁ-
ciently solve problems with thousands of variables and constraints
as demonstrated by the results of several constraint solver compe-
titions (e.g., [37] or [38]). Given our experience with the CPGs con-
sidered so far, the complexity of CLP-CPG models was (at least) an
order of a magnitude smaller – the number of variables did not ex-
ceed 100 and the number of constraints did not exceed 20. For CLP-
CPG models of such size we were able to get immediate results
(solving CLP-CPG models lasted less than 1 s when running the pi-
lot on a Motion Computing C5 tablet PC, often used as a mobile
computing platform in hospitals). Considering the scalability of
CLP solvers demonstrated by their extensive benchmarks, we be-
lieve the efﬁciency of the implemented algorithm should be
acceptable from a practical perspective, even for extremely large
and complex CPGs.
The next step is to integrate the pilot implementation of the
mitigation algorithmwith MET3 by embedding the pilot into a spe-
cialized mitigation agent. This agent will be available to other
agents in the system, especially an encounter assistant agent that
supports the physician throughout the entire patient management
process. Moreover, following recent research on CDSS architec-
tures, speciﬁcally on the service model [39], the mitigation agent
will expose its services to other hospital systems such as a comput-
erized physician order entry (CPOE) or an electronic patient record
(EPR) using a web-based interface. Such a service-orientedapproach has been adopted in several CDSSs (e.g., SEBASTIAN
[40], SANDS [41]) and has already demonstrated its capability for
easy integration of advanced decision support with existing hospi-
tal information systems [42]. Moreover, such a solution has been
mandated by the HL7 organization that proposed a standard for
decision support services [43].
The envisioned integration of the implemented algorithm with
the MET3 CDSS and other hospital information systems is pre-
sented in Fig. 18. Communication between agents within the
MET3 system follows standard FIPA protocols for multi-agent sys-
tems [35], while the service-oriented interface relies on standard
web-based technologies and protocols (like SOAP and REST) [41].
The MET3 system expanded with the mitigation agent will fully
support a complex patient management process aimed at develop-
ing the combined therapy. In addition to the already assisted steps
of the process (data collection, diagnosis and therapy planning),
the system will apply the mitigation algorithm to identify possible
adverse interactions, to warn the physician about them and to
present in advance possible ways of addressing them. According
to Fieschi et al. [44] an effective CDSS should place a physician at
the center of the decision making loop – this means that the sys-
tem would need to provide the user with all possible combined
therapies, and if adverse interactions between individual therapies
exist, with all possible ways of addressing them, and let the physi-
cian make the ultimate decision. The mitigation algorithm in its
current formulation is aimed at automatic execution. While deﬁn-
ing operators requires signiﬁcant involvement of clinical experts,
once all relevant operators have been supplied, the algorithm runs
without any interaction with the user, and it reports a single, arbi-
trary selected (i.e., ﬁrst found) therapy and revisions addressing
discovered interactions. However, it can be easily modiﬁed to act
as an assistant as opposed to an oracle – most of the changes would
be introduced in the address_PSI procedure (see Fig. 9) in order to
iterate over all applicable revision operators and to return multiple
solutions. Such changes to the mitigation algorithm should result
in better clinical acceptance of the CDSS implementing it.Acknowledgments
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